Literature DB >> 7915023

Single photon emission computed tomography with 123I-IMP in three cases of the neuroleptic malignant syndrome.

K Nisijima1, M Matoba, T Ishiguro.   

Abstract

Single photon emission computed tomography (SPECT) perfusion brain scans using 123I-N-isopropyl-p-iodoamphetamine (123I-IMP) were performed in three patients with the neuroleptic malignant syndrome (NMS). In two accumulation was increased in the left basal ganglia and decreased in the right on the early images during the active phase of NMS; this asymmetry was not seen after recovery. In the third patient two examinations were performed during the active phase; on the first, increased accumulation of 123I-IMP in the left basal ganglia was found on the early images, but on the second, increased accumulation of tracer was found in the right basal ganglia on the delayed images. These abnormalities disappeared after improvement of the NMS. These results suggest that a disturbance in the basal ganglia is related to the development of NMS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915023     DOI: 10.1007/bf00593260

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  13 in total

1.  Evaluation of the significance of "redistribution" in I-123 IMP SPECT in cerebrovascular disorders--a comparative study with PET.

Authors:  M Tsukuda; Y Kuwabara; Y Ichiya; M Otsuka; T Tahara; Y Miyake; M Mizuguchi; R Gunasekera; K Masuda
Journal:  Eur J Nucl Med       Date:  1989

2.  Neuroleptic malignant syndrome: review and analysis of 115 cases.

Authors:  G Addonizio; V L Susman; S D Roth
Journal:  Biol Psychiatry       Date:  1987-08       Impact factor: 13.382

Review 3.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

4.  Positron emission tomographic studies of changes in cerebral blood flow and oxygen metabolism in neuroleptic malignant syndrome.

Authors:  J De Reuck; J Van Aken; W Van Landegem; F Colardyn
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

5.  Early and delayed single photon emission CT in various cerebral diseases using N-isopropyl-p-(123I)iodoamphetamine.

Authors:  T Ueda; K Kinoshita; K Watanabe; H Hoshi; S Jinnouchi
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

6.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

7.  Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.

Authors:  M Toru; O Matsuda; K Makiguchi; K Sugano
Journal:  J Nerv Ment Dis       Date:  1981-05       Impact factor: 2.254

8.  Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.

Authors:  J E Granato; B J Stern; A Ringel; A H Karim; A Krumholz; J Coyle; S Adler
Journal:  Ann Neurol       Date:  1983-07       Impact factor: 10.422

9.  Cerebral dynamics of N-isopropyl-(123I)p-iodoamphetamine.

Authors:  H Creutzig; O Schober; P Gielow; R Friedrich; H Becker; H Dietz; H Hundeshagen
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

10.  N-isopropyl-[123I] p-iodoamphetamine: single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain.

Authors:  H S Winchell; W D Horst; L Braun; W H Oldendorf; R Hattner; H Parker
Journal:  J Nucl Med       Date:  1980-10       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.